(Q38448494)

3 September 2017

Her-2/neu gene amplification and protein expression in primary male breast cancer (English)

1 reference

3 September 2017

1 reference

Christian Rudlowski

1

1 reference

3 September 2017

Nicolaus Friedrichs

2

1 reference

3 September 2017

Andree Faridi

3

1 reference

3 September 2017

Lazlo Füzesi

4

1 reference

3 September 2017

Roland Moll

5

1 reference

3 September 2017

Gunther Bastert

6

1 reference

3 September 2017

Werner Rath

7

1 reference

3 September 2017

Reinhard Büttner

8

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Breast Cancer Research and Treatment

3 September 2017

1 reference

3 September 2017

84

1 reference

3 September 2017

3

1 reference

3 September 2017

215-223

1 reference

https://scigraph.springernature.com/pub.10.1023/b:brea.0000019953.92921.7e

3 September 2017

0 references

cites work

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

21 January 2018

Breast cancer in men.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

HER2 protein expression and gene amplification in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Herceptest: HER2 expression and gene amplification in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Breast cancer in the 21st century: neu opportunities and neu challenges

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Male breast cancer: a 22-year experience

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Male breast cancer: a review of the literature

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Status of HER-2 in male and female breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Molecular markers in male breast carcinoma.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis.

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Lack of c-erbB-2 oncoprotein expression in male breast carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Amplification of c-erbB-2 and aggressive human breast tumors?

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

A comparison outcome of male breast cancer with female breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival

1 reference

https://api.crossref.org/works/10.1023%2FB%3ABREA.0000019953.92921.7E

7 January 2021

10.1023/B:BREA.0000019953.92921.7E

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference